Alvotech Heats Up Patent Dispute Conflict by Suing AbbVie Over Humira Biosimilar

May 11th 2021, 8:15pm


Under the lawsuit, Alvotech alleges that AbbVie is unlawfully taking advantage of patent laws and claims courts to prevent biosimilar competition rivaling its blockbuster drug, Humira, from entering the US market.

Real-World Data From Multiple Sources May Be Needed to Conduct Biosimilar Comparison Studies

May 6th 2021, 9:47pm


Administrative claims data in oncology often lack sufficient information to conduct postmarketing comparison studies of biosimilars with their reference product, suggesting that other sources are needed to answer critical research questions.

Alberta, Canada, Begins Mandating Switches From Originator to Biosimilar Humira

May 5th 2021, 8:20pm


Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative.

Could Cyltezo Be the First Interchangeable Biosimilar in the United States?

April 30th 2021, 8:00pm


Despite the FDA approving 29 biosimilars, none have achieved interchangeability status. Boehringer Ingelheim thinks its adalimumab biosimilar, Cyltezo, may be the first.

Real-World Evidence on Biosimilar Adherence and Adoption

April 28th 2021, 1:45pm


Posters from the Academy of Managed Care Pharmacy annual meeting evaluated real-world evidence on adherence to biosimilars and barriers to biosimilar adoption.

Mandatory Biosimilar Switching Pays Off for Canada

April 22nd 2021, 1:30pm


For Alberta and Green Shield Canada, savings are beginning to add up from switching initiatives for multiple reference biologics.

Study Supports Off-label Use of Infliximab Biosimilar in HS

April 20th 2021, 1:30pm


Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking.

Drs Rebecca Borgert and Jim Rebello Discuss What Could Persuade Payers to Use Biosimilars

April 15th 2021, 7:58pm


Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management, discussed what evidence they believe could persuade payers to include biosimilars as preferred formulary products.

Biosimilars Advance in the Oncology Space

April 12th 2021, 6:00pm


Hospital reimbursement deals slow the adoption of biosimilars in oncology, but cost concerns contribute to the incentives to use these agents.

Employer Opportunities With Biosimilars

August 11th 2020, 8:45pm